相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase
Emiel Rutgers et al.
EUROPEAN JOURNAL OF CANCER (2011)
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
Shuzhen Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Combinatorial biomarker expression in breast cancer
Emad A. Rakha et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer
Marie Klintman et al.
MODERN PATHOLOGY (2010)
Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer
So-Youn Jung et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
Pratyaksha Wirapati et al.
BREAST CANCER RESEARCH (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
Tutorial in biostatistics: Competing risks and multi-state models
H. Putter et al.
STATISTICS IN MEDICINE (2007)
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
M Colozza et al.
ANNALS OF ONCOLOGY (2005)
Proliferation marker Ki-67 in early breast cancer
A Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years
JPA Baak et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A pooled analysis of bone marrow micrometastasis in breast cancer
S Braun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Proliferative activity in primary breast carcinomas is a salient prognostic factor
JJ Michels et al.
CANCER (2004)
Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines
B Baldetorp et al.
CYTOMETRY PART A (2003)
Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy
J Boyages et al.
BRITISH JOURNAL OF SURGERY (2002)
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
F Jänicke et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
M Ferno et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
分享论文
